GAF® formalin free fixative: the first fully efficient, nontoxic, non cancerogenic histological fixative available on the market.

Thanks to its patented innovative production process, which includes the acid deprivation, GAF provides formalin-analogous performances along the full path of biopsy diagnostic, for the benefit of patients and medical teams. Many attempts have been done over the past decades in finding a safe formalin substitute. All attempts failed due to inability to offer acceptable diagnostic performances. GAF provides analogous or better fixative capacity in the full range of application of formalin, while neutralising associated oncology risks for healthcare workers. Formalin progressive substitution with GAF will primarily prevent hospital workers from risk of oncology events. Complying with EU regulation n. 895/2014, main GAF societal benefit is protecting healthcare professionals from developing lung disease and respiratory tracts cancer, while preserving the accuracy of the diagnosis for the benefit of doctors and patients. GAF brings additional benefits, such as environmental improvements due to lower air pollutants emission, lower toxicological impact for waste disposal, absence of procedural and operational countermeasures for routinary health surveillance, insurance cost reduction, and lower risk for legal sanctions and complaints.